The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

The increased prevalence of obesity presents challenges for clinicians aiming to provide
optimised antimicrobial dosing in the intensive care unit. Obesity is likely to exacerbate the …

Objectives The objectives of this study were to determine the effects of obesity on unbound
trough concentrations and on the achievement of pharmacokinetic (PK)/pharmacodynamic …

Piperacillin-tazobactam is frequently used for empirical and targeted therapy of infections in
critically ill patients. Considerable pharmacokinetic (PK) variability is observed in critically ill …

The objectives of this study were (i) to compare the plasma concentration–time profiles for
first-dose and steady-state piperacillin administered by intermittent or continuous dosing to …